Latest News From Lumira Ventures

Cardiac Dimensions Announces Positive Late-Breaking Results for Blinded Clinical Trial of Minimally Invasive Heart Failure Treatment

Ahmed Khan Portfolio News

In Randomized Blinded Study, the Carillon Mitral Contour System Catheter-Based Treatment Meets Endpoint for Reduction in Regurgitant Volume KIRKLAND, Wash.- Cardiac Dimensions, a leader in the development of innovative, minimally invasive treatment modalities to address heart failure and related cardiovascular …

G1 Therapeutics to Report Myelopreservation Data from Randomized Phase 2 Trial of Trilaciclib/Chemotherapy/Tecentriq® in Small Cell Lung Cancer in Fourth Quarter 2018

Ahmed Khan Portfolio News

G1 Therapeutics (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it is expediting analyses of myelopreservation data from its randomized Phase 2 trial of trilaciclib in combination with chemotherapy and Tecentriq® (atezolizumab) in first-line small cell lung cancer (SCLC). Myelopreservation results …

Highlights from CTA@Boston

Ahmed Khan Lumira News

The Consulate General of Canada in Boston and the Trade Commissioner Service has announced highlights of the Canadian Technology Accelerator in Boston.   Lumira Ventures’ Boston-based partner Gerry Brunk has served as a team member and lead mentor for the CTA …